PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Advanced Cancer Research Workflows

Principle Overview: Harnessing FAK/Pyk2 Inhibition in Cancer Biology

Focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2) are non-receptor tyrosine kinases crucially involved in cellular adhesion, migration, proliferation, and survival. Aberrant activation of the focal adhesion kinase signaling pathway has been tightly linked to tumor progression, metastasis, and resistance to therapy—making these kinases prime targets in translational oncology.

PF-562271 HCl (SKU: A8345), provided by APExBIO, is a potent, reversible FAK/Pyk2 inhibitor with exceptional selectivity and nanomolar potency. As an ATP-competitive FAK inhibitor, it features an IC50 of 1.5 nM for FAK and 14 nM for Pyk2—demonstrating over 100-fold selectivity against most other protein kinases (with minimal off-target CDK activity). This biochemical profile enables researchers to dissect the FAK and Pyk2 signaling axes with unparalleled specificity for both tumor growth inhibition and tumor metastasis research.

Recent research, such as the multi-institutional study by Adams et al. (Cancer Letters, 2025), has illuminated the pivotal role of FAK/Pyk2 in orchestrating the migratory behavior of myeloid progenitor cells and circulating tumor cells (CTCs) during pre-metastatic niche formation. By targeting these kinases, PF-562271 HCl provides a direct tool to interrogate and disrupt metastatic processes at the molecular level.

Step-by-Step Experimental Workflow: Protocol Optimization with PF-562271 HCl

Compound Handling and Solubility

• Storage: Store PF-562271 HCl at -20°C for maximal stability. Avoid repeated freeze-thaw cycles to maintain compound integrity.
• Solubility: The compound is highly soluble in DMSO (≥26.35 mg/mL with gentle warming), but insoluble in water and ethanol. For in vitro applications, prepare concentrated DMSO stock solutions and dilute to final concentrations in culture medium, ensuring that the DMSO content remains below 0.1% v/v for cell-based assays.

Cell-based Assays: Tumor Growth and Metastasis Models

1. Cell Seeding: Plate target cancer cell lines (e.g., pancreatic, breast, or lung carcinoma) at the desired density in multiwell plates (typically 24- or 96-well format).
2. Compound Treatment: Dilute PF-562271 HCl in pre-warmed culture medium. Titrate across a range (e.g., 0.1 nM to 5 μM) to establish dose-response curves for cell viability, migration, or invasion.
3. Assay Readouts:
   • FAK phosphorylation inhibition: Quantify phospho-FAK (Y397) by Western blot or ELISA after 2–24 hours of treatment. The compound demonstrates dose-dependent suppression with an EC50 of 93 ng/mL in tumor models.
   • Cell migration/invasion: Perform scratch (wound healing) or transwell assays to assess the impact on cellular motility.
   • Proliferation: Utilize MTT, WST-1, or ATP-based assays to measure cell viability and proliferation as a function of FAK/Pyk2 inhibition.
4. Advanced Models: For xenograft tumor model inhibition or transgenic mouse tumor models, PF-562271 HCl can be administered via intraperitoneal or oral routes, following validated dosing regimens (typically 33 mg/kg/day in published studies) to achieve robust tumor growth inhibition and microenvironment modulation.

For detailed scenario-driven protocols and troubleshooting, refer to the article "PF-562271 HCl (SKU A8345): Scenario-Driven Solutions for Cancer Research", which complements this guide by addressing real-world laboratory challenges and providing data-backed workflow optimizations.

Advanced Applications and Comparative Advantages

Dissecting Tumor Microenvironment and Metastatic Niche Formation

PF-562271 HCl’s selectivity as a reversible focal adhesion kinase inhibitor offers a unique advantage in studying the dynamic interplay between tumor cells and the microenvironment. The reference study by Adams et al. (2025) demonstrates how FAK/Pyk2 signaling modulates the transformation and migration of myeloid progenitor cells (MPCs) and the formation of pre-metastatic niches—key steps in early metastasis. By inhibiting these pathways, PF-562271 HCl enables researchers to:

• Block recruitment of pro-tumorigenic myeloid cells to future metastatic sites, interrupting the establishment of supportive microenvironments.
• Restrict CTC homing and extravasation, impeding the colonization of distant organs by tumor cells.
• Probe the role of FAK/Pyk2 in immune-tumor crosstalk, particularly in the context of tumor-immune evasion and resistance.

These attributes are explored in greater depth in "PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Cancer Research" and "Unveiling FAK/Pyk2 Inhibition in Tumor Immunity", which respectively complement and extend the workflow approaches discussed here. The former offers a technical deep-dive into FAK pathway dissection, while the latter explores immune modulation and the broader impact on tumor microenvironment.

Pancreatic and Solid Tumor Research: Quantified Performance

In preclinical models, PF-562271 HCl has been shown to:

• Reduce tumor proliferation and metastatic burden in xenograft and transgenic mouse models, with significant suppression of tumor growth rates and metastatic lesion formation.
• Inhibit FAK phosphorylation with an EC50 of 93 ng/mL, supporting precise titration in both in vitro and in vivo assays.
• Demonstrate >100-fold selectivity over non-target kinases, reducing off-target effects and maximizing data interpretability.

Comparative analyses (see "PF-562271 HCl: A Next-Generation FAK/Pyk2 Inhibitor for Tumor Microenvironment Modulation") highlight its superiority over older FAK inhibitors, particularly in terms of selectivity and reversible, ATP-competitive inhibition—critical for dissecting transient signaling events and resistance mechanisms in cancer cell populations.

Troubleshooting and Optimization Tips

• Solubility Challenges: If PF-562271 HCl fails to dissolve completely in DMSO, gently warm the solution to 37°C and vortex. Avoid sonication, which may degrade the compound.
• Compound Precipitation: When diluting into aqueous buffers or cell culture medium, add DMSO stock slowly with constant agitation. Pre-warm the medium to reduce precipitation risk.
• Assay Artifacts: Maintain DMSO concentrations below 0.1% in cell-based assays to avoid solvent toxicity. Include DMSO-only controls to distinguish compound-specific effects.
• FAK Phosphorylation Detection: Use validated antibodies for p-FAK (Y397) and normalize to total FAK or housekeeping proteins. For low-abundance cell lines, consider using enhanced chemiluminescence or digital imaging systems.
• In Vivo Dosing: Monitor animal weight and health regularly; adjust dosing schedules based on pharmacokinetic data. PF-562271 HCl is typically well-tolerated at standard research doses, but confirm with pilot studies in your specific model.

For more troubleshooting guidance and real-world protocol adjustments, "Scenario-Driven Solutions in FAK/Pyk2 Inhibitor Research" provides complementary insights focused on data reliability and workflow efficiency.

Future Outlook: Translational Impact and Emerging Directions

As the clinical significance of FAK/Pyk2 signaling becomes increasingly evident in cancer progression and therapy resistance, PF-562271 HCl is set to remain a cornerstone tool for basic and translational oncology. Ongoing research leverages its robust profile to:

• Elucidate mechanisms of metastatic niche initiation and the role of MPCs/CTCs in organ-specific colonization, as underscored by Adams et al. (2025).
• Advance combination therapy studies, integrating FAK/Pyk2 inhibition with immunotherapies or cytotoxic agents to counteract resistance and improve patient outcomes.
• Enable personalized cancer therapy research, using PF-562271 HCl as a molecular probe to stratify tumors based on FAK/Pyk2 dependency and microenvironmental context.
• Drive innovation in solid tumor and pancreatic cancer models, supporting discovery of biomarkers and next-generation therapeutic strategies.

APExBIO’s commitment to quality and reproducibility ensures that PF-562271 HCl remains a trusted choice for investigators worldwide seeking reliable FAK/Pyk2 pathway inhibition in their cancer research workflows.

Conclusion

PF-562271 HCl exemplifies the next generation of selective, reversible FAK/Pyk2 inhibitors—enabling researchers to dissect the molecular underpinnings of tumor progression, metastasis, and microenvironmental modulation. With validated protocols, robust selectivity, and comprehensive data support, it is an essential asset for any laboratory engaged in cancer therapy research, cell migration inhibition, and preclinical drug discovery.

To order or learn more about PF-562271 HCl, visit the official APExBIO product page.